Opinion on Pharmaceutical Manufacturers

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Eli Lilly's Alimta to change the treatment dynamics in non-small cell lung cancer

Eli Lilly's Alimta is set for launch in the US market having gained FDA approval for the treatment of lung cancer, caused by exposure to asbestos, in patients who are not candidates for surgery. Although likely to become the gold standard treatment in this area, Alimta could have a far greater impact on the wider market if approved for the treatment of non-small cell lung cancer.

Published By Datamonitor
01 Apr 2004
CommentWire
CommentWire

Aventis: Ketek shows its blockbuster potential

The FDA has approved Ketek tablets, the first in a new class of antibiotics known as ketolides that are specifically designed to treat community-acquired respiratory tract infections (RTIs). If Aventis [AVE.L] markets the drug effectively to the wider healthcare community, it could prove to be a major success.

Published By Datamonitor
06 Apr 2004
Expert View
Expert View

An increasing incidence of HIV/HBV co-infection calls for more effective treatment

According to recent research the rate of hepatitis B co-infection in HIV infected individuals is increasing among the seven major markets. Although the advent of Highly Active Antiretroviral Therapy has led to increased longevity in those infected with HIV, this has consequently led to an increasing prevalence of chronic co-infections such as hepatitis B and hepatitis C.

Published By Datamonitor
08 Apr 2004
Expert View
Expert View

Fluoroquinolone use set to increase, despite resistance warnings

New research from Datamonitor suggests that increasing reports of bacterial resistance to older drugs will drive uptake of fluoroquinolones, a class of broad-spectrum antibiotics, despite warnings of decreasing sensitivities and adverse events. The extensive pathogen activity exhibited by these compounds is set to create significant challenges for companies looking to introduce novel products.

Published By Datamonitor
23 Apr 2004
Expert View
Expert View

R&D innovations to drive growth in osteoporosis market

With key R&D trends in the field of osteoporosis treatments focusing on novel dosing regimens and expanded indications, the market is set for strong growth driven by new product entrants. A flurry of launch activity is expected between 2004-8 and six key products should reach the market in this time. Research from Datamonitor analyzes the products and trends likely to spur this growth.

Published By Datamonitor
30 Apr 2004
CommentWire
CommentWire

Wyeth: wider benefits for Prevnar

Research from Kaiser Permanente suggests that widespread immunization with Prevnar reduces the incidence of pneumococcal infections in adults and older children. This and other similar studies should help to establish greater demand for Prevnar, which has yet to entirely fulfill its potential due to its relatively high cost.

Published By Datamonitor
05 May 2004
Expert View
Expert View

Roche pipeline to fuel future growth

Swiss pharmaceuticals group Roche has this week held an R&D day to highlight its drug pipeline and the products that are expected to drive its future revenue growth. Having recently recovered from a period of difficulty, Roche has now said that it has 12 drugs, either on the market or in late-stage development, each with peak annual sales potential of more than one billion Swiss francs ($778m).

Published By Datamonitor
07 May 2004
CommentWire
CommentWire

GW Pharmaceuticals: high expectations for cannabis drug

GW Pharmaceuticals [GWP.L] and Bayer Healthcare [BAY.F] have submitted a New Drug Submission for Sativex, a cannabis-based medicine for the symptomatic treatment of multiple sclerosis (MS) and neuropathic pain, to Health Canada. This move will help generate optimism regarding Sativex, offering renewed hope for manufacturers and patients alike.

Published By Datamonitor
13 May 2004
CommentWire
CommentWire

Johnson & Johnson MSD: OTC statins launched in the UK

Over-the-counter simvastatin is expected to be launched under the brand name of Zocor Heart-Pro and will be available at a daily dose of 10mg. Though the move has been criticized for putting patients at potential risk, it should help statin manufacturers offset declining revenues from generic competition.

Published By Datamonitor
13 May 2004
Expert View
Expert View

Generic antihistamines compete as the hay fever season begins

The price of the generic non-sedating antihistamine loratadine is falling in response to the demand for treatment as the US enters the hay fever season. Datamonitor's Clare Churchill looks at the strategies pharma companies are employing in an attempt to hang on to market share in the face of genericization...

Published By Datamonitor
18 May 2004

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.